Skip to main content

Table 2 Longitudinal studies in populations including Down syndrome

From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

Study Subjects Mean age (years) Follow-up duration Platform and antibodies CV Analyte associated with conversion risk Magnitude
Schupf et al. 2007 [32] 44 DSp - 5 yearsa ELISA - baseline Aβ1-42 HR = 2.6
  130 cnDS    6E10    
     R182    
     R165    
Schupf et al. 2010 [33] 61 DSp 53.7 - ELISA - Decrease of Aβ1-40 HR = 0.4
  164 cnDS 50.3   6E10   Stable Aβ1-42 HR = 2.6
     R182   Decrease Aβ1-42 HR = 4.9
     R165   Stable Aβ1-42/Aβ1-40 HR = 3.9
       Decrease Aβ1-42/Aβ1-40 HR = 4.9
Coppus et al. 2012 [54] 79 DSp 53.3 - xMAP   ↑ baseline Aβ1-40 HR = 2.05
  264 cnDS 50.6   INNO-BIA   ↑ baseline Aβ1-42 HR = 2.56
  1. aEstimated by author of review. cnDS, cognitively normal Down syndrome; CV, coefficient of variation; DSp, Down syndrome subjects who progress to a dementia diagnosis; HR, hazard ratio.